Single-cell Landscape of Innate and Acquired Drug Resistance in Acute Myeloid Leukemia

Deep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine single-cell ex vivo drug profiling (pharmacoscopy) with single-cell and bulk DNA, RNA, and protein analyses, alongside clinical data from 21 rrAML patients. Unsupervised data integration reveals reduced ex vivo response to the Bcl-2 inhibitor venetoclax (VEN) in patients treated with both a hypomethylating agent (HMA) and VEN, compared to those pre-exposed to chemotherapy or HMA alone. Integrative analysis identifies both known and unreported mechanisms of innate and treatment-related VEN resistance and suggests alternative treatments, like targeting increased proliferation with the PLK inhibitor volasertib. Additionally, high CD36 expression in VEN-resistant blasts associates with sensitivity to CD36-targeted antibody treatment ex vivo. This study demonstrates how single-cell multi-omic profiling can uncover drug resistance mechanisms and treatment vulnerabilities, providing a valuable resource for future AML research.

References

Kornauth C, Pemovska T, Vladimer G, Bayer G, Bergmann M, Eder S . Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 2021; 12(2):372-387. PMC: 9762339. DOI: 10.1158/2159-8290.CD-21-0538. View

Haghverdi L, Lun A, Morgan M, Marioni J . Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol. 2018; 36(5):421-427. PMC: 6152897. DOI: 10.1038/nbt.4091. View

Ong F, Kim K, Konopleva M . Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022; 5(2):380-400. PMC: 9255248. DOI: 10.20517/cdr.2021.125. View

Liebers N, Bruch P, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D . Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial. Nat Cancer. 2023; 4(12):1648-1659. PMC: 10733146. DOI: 10.1038/s43018-023-00645-5. View

Irmisch A, Bonilla X, Chevrier S, Lehmann K, Singer F, Toussaint N . The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell. 2021; 39(3):288-293. DOI: 10.1016/j.ccell.2021.01.004. View

Prummer M, Bertolini A, Bosshard L, Barkmann F, Yates J, Boeva V . scROSHI: robust supervised hierarchical identification of single cells. NAR Genom Bioinform. 2023; 5(2):lqad058. PMC: 10273189. DOI: 10.1093/nargab/lqad058. View

Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

cuklina J, Lee C, Williams E, Sajic T, Collins B, Rodriguez Martinez M . Diagnostics and correction of batch effects in large-scale proteomic studies: a tutorial. Mol Syst Biol. 2021; 17(8):e10240. PMC: 8447595. DOI: 10.15252/msb.202110240. View

Heinemann T, Kornauth C, Severin Y, Vladimer G, Pemovska T, Hadzijusufovic E . Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine. Blood Cancer Discov. 2022; 3(6):502-515. PMC: 9894727. DOI: 10.1158/2643-3230.BCD-21-0219. View

10.

Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K . Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022; 40(8):850-864.e9. PMC: 9378589. DOI: 10.1016/j.ccell.2022.07.002. View

11.

Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y . Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020; 11(1):5327. PMC: 7577981. DOI: 10.1038/s41467-020-19119-8. View

12.

DiNardo C, Lachowiez C, Takahashi K, Loghavi S, Xiao L, Kadia T . Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021; 39(25):2768-2778. PMC: 8407653. DOI: 10.1200/JCO.20.03736. View

13.

Kurtz S, Eide C, Kaempf A, Khanna V, Savage S, Rofelty A . Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017; 114(36):E7554-E7563. PMC: 5594650. DOI: 10.1073/pnas.1703094114. View

14.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A . Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-29. DOI: 10.1158/2159-8290.CD-13-0350. View

15.

Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R . Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020; 1(8):826-839. PMC: 7591155. DOI: 10.1038/s43018-020-0103-x. View

16.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

17.

Foroutan M, Bhuva D, Lyu R, Horan K, Cursons J, Davis M . Single sample scoring of molecular phenotypes. BMC Bioinformatics. 2018; 19(1):404. PMC: 6219008. DOI: 10.1186/s12859-018-2435-4. View

18.

Bhatt S, Pioso M, Olesinski E, Yilma B, Ryan J, Mashaka T . Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020; 38(6):872-890.e6. PMC: 7988687. DOI: 10.1016/j.ccell.2020.10.010. View

19.

Chen X, Glytsou C, Zhou H, Narang S, Reyna D, Lopez A . Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discov. 2019; 9(7):890-909. PMC: 6606342. DOI: 10.1158/2159-8290.CD-19-0117. View

20.

Tislevoll B, Hellesoy M, Fagerholt O, Gullaksen S, Srivastava A, Birkeland E . Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Nat Commun. 2023; 14(1):115. PMC: 9825407. DOI: 10.1038/s41467-022-35624-4. View